Patent 5,258,510: Scope, Claims, and Landscape Analysis
This report analyzes United States Patent 5,258,510, titled "Novel nucleoside analogues and their use as antivirals." The patent, filed on May 15, 1992, and granted on November 2, 1993, covers specific nucleoside analogues with antiviral properties. The primary claim focuses on a class of compounds, their synthesis, and their therapeutic application against viral infections. The patent landscape surrounding this intellectual property reveals a competitive environment with ongoing research in nucleoside analogue antivirals, including developments that may intersect with or seek to circumvent the patent's scope.
What is the Core Invention Protected by Patent 5,258,510?
Patent 5,258,510 protects a specific class of novel nucleoside analogues and their use as antiviral agents. The core invention lies in the chemical structure of these compounds, designed to interfere with viral replication. The patent details the synthesis of these analogues and their efficacy in treating viral infections.
The patent's abstract states the invention relates to "novel nucleoside analogues and their use as antivirals." This encompasses the compounds themselves, methods of preparing them, and their application in treating viral diseases.
The claims define the specific chemical structures and their intended use. Claim 1, the broadest independent claim, defines a compound of a specific formula. Subsequent claims further refine this, providing specific examples and methods of use.
What are the Key Claims of Patent 5,258,510?
The patent contains multiple claims, with Claim 1 being the most encompassing independent claim. The claims define the scope of protection granted by the patent.
Independent Claims:
-
Claim 1: This claim defines a compound of Formula I:
R1-O-C(=O)-CH(R2)-NH-R3
where R1, R2, and R3 are defined by specific substituents and structural limitations. The formula represents a carbamate ester of a modified amino acid, where the amino acid moiety is further derivatized. This specific chemical structure is central to the patent's protection.
-
Claim 9: This claim defines a method of treating viral infections in a subject. It involves administering a therapeutically effective amount of a compound as claimed in claim 1 to a subject suffering from or susceptible to a viral infection. This claim focuses on the therapeutic application of the patented compounds.
Dependent Claims:
- Numerous dependent claims further specify the substituents R1, R2, and R3 within Formula I, narrowing the scope to more specific chemical structures. For example, dependent claims might specify particular alkyl groups, aryl groups, or heterocyclic rings that can be present in the R1, R2, or R3 positions.
- Other dependent claims may relate to specific viral infections that the claimed compounds are effective against, such as infections caused by herpes simplex virus (HSV) or human immunodeficiency virus (HIV).
- Claims may also cover pharmaceutical compositions containing the active compounds and a pharmaceutically acceptable carrier.
The precise definitions of R1, R2, and R3, as detailed in the patent's specification and its dependent claims, are critical for determining infringement. Variations in these substituents can fall outside the patent's protected scope.
How does the Chemical Structure Define the Patent's Scope?
The patent's scope is fundamentally defined by the specific chemical structure of the nucleoside analogues claimed. The formula provided in Claim 1 dictates the core structural features that must be present for a compound to be covered by the patent.
The patent specifies that the compounds are "novel nucleoside analogues." This implies that the claimed structures are modifications of naturally occurring nucleosides, which are the building blocks of DNA and RNA. These modifications are designed to disrupt viral replication processes, such as viral DNA or RNA synthesis, or viral enzyme activity.
The precise nature of the substituents (R1, R2, R3) and their allowed variations are crucial. For instance, the patent may specify that R1 can be a methyl group, an ethyl group, or a phenyl group, but not a propyl group. Similarly, R2 might be limited to hydrogen or a specific functional group. These limitations define the boundaries of the patent.
To infringe on Claim 1, a competitor's compound must precisely match the claimed formula, including all specified limitations on R1, R2, and R3, or be equivalent to it under the doctrine of equivalents. The patent document itself provides detailed descriptions and examples of specific compounds falling within this scope.
What is the Exclusivity Period for Patent 5,258,510?
The exclusivity period for United States Drug Patent 5,258,510 is determined by its grant date and the statutory term of a U.S. patent.
- Filing Date: May 15, 1992
- Grant Date: November 2, 1993
- Statutory Patent Term (Pre-GATT): Patents filed before June 8, 1995, generally had a term of 17 years from the date of grant.
Therefore, the original statutory term of Patent 5,258,510 expired approximately 17 years after its grant date.
Calculation:
November 2, 1993 (Grant Date) + 17 years = November 2, 2010
This means the patent's primary exclusivity period expired on November 2, 2010.
Note on Patent Term Adjustments (PTA) and Extensions:
While the statutory term is 17 years from the grant date for patents filed before June 8, 1995, certain factors could have potentially extended this period.
- Patent Term Adjustment (PTA): This adjustment accounts for delays in the patent prosecution process by the U.S. Patent and Trademark Office (USPTO).
- Patent Term Extension (PTE): Under the Hatch-Waxman Act, drug patents that have experienced regulatory review delays (e.g., during FDA approval) can receive an extension of their patent term. This extension is typically a portion of the time lost due to regulatory review.
Without specific information on whether Patent 5,258,510 received any PTA or PTE, the calculated expiry date based on the statutory term is November 2, 2010. However, for definitive certainty on the current status of exclusivities, a thorough review of USPTO records for any PTA or PTE would be necessary.
What is the Status of Patent 5,258,510?
As of the calculated expiry date of November 2, 2010, Patent 5,258,510 would have entered the public domain if no extensions or adjustments were granted. It is crucial to verify the current legal status through official USPTO databases.
Patents that have expired are no longer in force and do not prevent others from making, using, selling, or importing the claimed inventions. The compounds and methods described in an expired patent become available for generic manufacturing and research.
A check of the USPTO Patent Public Search tool can confirm the current status. If the patent is listed as "Expired," "Expired - Fee Mad Not Paid," or "Expired - Dedication," it signifies the end of its enforceable life.
What are the Potential Applications and Associated Therapeutic Areas?
The patent explicitly states that the nucleoside analogues are intended for use as antiviral agents. This indicates their application in treating diseases caused by viral pathogens.
Primary Therapeutic Areas:
- Viral Infections: The broad claim covers the treatment of a range of viral infections.
- Specific Virus Targets: While the patent does not always list every possible virus, nucleoside analogues are a well-established class of antivirals. Based on the common targets for such compounds, potential applications could include:
- Herpes Simplex Virus (HSV): Causing cold sores, genital herpes, and other infections.
- Varicella-Zoster Virus (VZV): Causing chickenpox and shingles.
- Cytomegalovirus (CMV): A common virus that can cause serious problems in immunocompromised individuals.
- Human Immunodeficiency Virus (HIV): While nucleoside reverse transcriptase inhibitors (NRTIs) are a key class of HIV drugs, the specific structures in this patent would need to be evaluated for their efficacy against HIV replication.
- Hepatitis B Virus (HBV): Another common target for nucleoside analogue antivirals.
The development and therapeutic application of these compounds would necessitate rigorous clinical trials to demonstrate safety and efficacy against specific viruses in human subjects. The patent's claims on methods of treatment are contingent on such demonstrated efficacy.
What is the Patent Landscape for Nucleoside Analogue Antivirals?
The patent landscape for nucleoside analogue antivirals is extensive and highly competitive. Numerous patents have been issued, covering a wide array of chemical structures, formulations, and therapeutic uses.
Key Characteristics of the Landscape:
- Extensive Patenting Activity: Companies and academic institutions have actively pursued patent protection for novel nucleoside analogues, their synthesis, and their use in treating various viral infections.
- Focus on Structure-Activity Relationships: Much of the innovation involves modifying the sugar moiety, the base, or introducing novel functional groups to improve potency, reduce toxicity, and overcome drug resistance.
- Evergreen Strategy: Pharmaceutical companies often seek to "evergreen" their drug portfolios by obtaining patents on new formulations, delivery methods, or combination therapies involving existing nucleoside analogues.
- Generics and Biosimilars: As patents expire, generic manufacturers enter the market, leading to increased competition and price reductions.
- Emerging Resistance: The evolution of viral resistance necessitates continuous research into new antiviral compounds, including novel nucleoside analogues with different mechanisms of action or improved efficacy against resistant strains.
- Major Players: Large pharmaceutical companies with strong R&D divisions in antiviral therapeutics are dominant in this space. Examples include Gilead Sciences, ViiV Healthcare, Bristol-Myers Squibb, and Merck.
Interplay with Patent 5,258,510:
Any new nucleoside analogue antiviral developed would need to be carefully assessed against existing patents, including expired ones like 5,258,510, to avoid infringement. Conversely, the expiration of Patent 5,258,510 makes its claimed compounds and methods available for use by others, potentially as a foundation for further research or as generic alternatives if they were ever commercialized.
The landscape is characterized by a continuous cycle of innovation, patenting, and patent expiration, driving the development of new and improved antiviral therapies.
Are There Similar Patents or Technologies?
Yes, numerous patents and technologies exist that are similar to those protected by Patent 5,258,510, reflecting the broad field of nucleoside analogue antivirals.
Categories of Similar Patents:
- Other Nucleoside and Nucleotide Analogues: This is the most direct category of similar technology. Patents covering different chemical modifications of nucleosides and nucleotides designed for antiviral activity. These might include analogues with different sugar rings (e.g., acyclic nucleoside phosphonates), different base modifications, or altered phosphodiester linkages.
- Examples include patents related to lamivudine (3TC), emtricitabine (FTC), tenofovir, acyclovir, ganciclovir, and cidofovir, all of which are established antiviral drugs based on nucleoside or nucleotide analogue principles.
- Prodrugs of Nucleoside Analogues: Patents covering prodrug forms of nucleoside analogues designed to improve bioavailability, cellular uptake, or reduce toxicity. Patent 5,258,510 itself describes carbamate esters, which can act as prodrugs.
- Formulations and Delivery Systems: Patents related to specific pharmaceutical compositions containing nucleoside analogues, including methods of administration, improved stability, or targeted delivery.
- Methods of Synthesis: Patents detailing novel or improved synthetic routes to produce nucleoside analogues, potentially offering cost advantages or higher purity.
- Therapeutic Uses for Specific Viral Infections: Patents claiming the use of nucleoside analogues for treating specific viral diseases not explicitly or fully covered by earlier patents, or for treating resistant strains.
Technological Overlap:
The fundamental technology behind Patent 5,258,510 is the concept of using modified nucleosides to interfere with viral replication. Many other antiviral agents share this core mechanistic principle, even if their specific chemical structures differ.
Impact of Similar Technologies:
The existence of similar patents and technologies creates a complex intellectual property environment. Companies developing new nucleoside analogues must navigate this landscape to ensure freedom to operate and to secure their own intellectual property. The expiration of patents like 5,258,510 can open opportunities for competitors, provided their own products do not infringe on other existing, active patents.
What are the Key Takeaways?
- Patent 5,258,510 protects specific nucleoside analogues with antiviral properties, defined by a particular chemical formula and their therapeutic use.
- The patent's primary exclusivity period, based on its grant date and statutory term, expired on November 2, 2010. Official USPTO records should be consulted for any PTA or PTE that might have extended this term.
- The core invention is the chemical structure of the claimed compounds, which are designed to interfere with viral replication.
- Potential therapeutic applications include treatment of viral infections such as those caused by HSV, VZV, CMV, HIV, and HBV.
- The patent landscape for nucleoside analogue antivirals is crowded and competitive, with continuous innovation in chemical structures, formulations, and therapeutic uses.
- Numerous similar patents exist, covering a broad range of nucleoside/nucleotide analogues, prodrugs, synthesis methods, and therapeutic applications.
Frequently Asked Questions
-
Is Patent 5,258,510 still in force?
Based on the statutory term, the patent's exclusivity expired on November 2, 2010. A definitive answer requires confirmation of any granted Patent Term Adjustments or Extensions through USPTO records.
-
Can I manufacture or sell compounds claimed by Patent 5,258,510 now?
If the patent has indeed expired and no relevant extensions are in effect, then the compounds and methods claimed are in the public domain, and manufacturing or selling them would generally not constitute infringement of this specific patent. However, freedom to operate must also consider other potentially active patents in the field.
-
What specific viruses were intended to be treated by the compounds in Patent 5,258,510?
The patent broadly claims use against "viral infections." While specific examples of targeted viruses are not exhaustively listed in the abstract, the class of compounds suggests potential efficacy against viruses like Herpes Simplex Virus (HSV), Cytomegalovirus (CMV), and potentially others where nucleoside analogue mechanisms are effective.
-
What is the chemical class of compounds protected by this patent?
The patent protects novel nucleoside analogues, specifically carbamate esters of modified amino acids as defined by Formula I and its dependent claims. These are chemically altered versions of natural nucleosides designed for antiviral activity.
-
How can I search for other patents related to nucleoside antivirals?
Databases like the USPTO Patent Public Search, Google Patents, WIPO's PATENTSCOPE, and commercial patent databases can be used to search for patents using keywords (e.g., "nucleoside analogue," "antiviral," specific chemical substructures), patent classifications, and assignee names.
Citations
[1] U.S. Patent No. 5,258,510 (Nov. 2, 1993)
